

APR 09 2007

Atty Docket No. 02307O-115611US

PTO FAX NO.: 1-571-273-8300

ATTENTION: Examiner Brian Yong Kwon

Group Art Unit 1614

OFFICIAL COMMUNICATION
FOR THE PERSONAL ATTENTION OF
EXAMINER Brian Yong Kwon

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following documents in re Application of Deanna L. KROETZ et al., Application No. 10/694,641, filed October 27, 2003 for INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF HYPERTENSION are being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Documents Attached

1. Communication Transmitting Terminal Disclaimer 2 pzges)
2. PTO/SB/26 - Terminal Disclaimer (1 page)
3. PTO/SB/17 - Fee Transmittal (1 sheep in duplicate)

Number of pages being transmitted, including this page: 6

Dated: 4/9/06



Lata Olivier

**PLEASE CONFIRM RECEIPT OF THIS PAPER BY
RETURN FACSIMILE AT (415) 576-0300**

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, CA 94111-3834
Telephone: 415-576-0200
Fax: 415-576-0300
0326

61025850 v1

RECEIVED
CENTRAL FAX CENTER

002/006

APR 09 2007

I hereby certify that this correspondence is being facsimile
transmitted to the United States Patent and Trademark Office,
Fax No. 1-571-273-8300 on April 9, 2007

PATENT

Attorney Docket No.: 023070-115611US

Client Ref. No.: 2000-094-3

TOWNSEND and TOWNSEND and CREW LLP

By: 
Lata Olivier

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

KROETZ et al.

Application No.: 10/694,641

Filed: October 27, 2003

For: INHIBITORS OF EPOXIDE
HYDROLASES FOR THE
TREATMENT OF HYPERTENSION

Customer No.: 20350

Confirmation No. 4011

Examiner: Brian Yong Kwon

Technology Center/Art Unit: 1614

COMMUNICATION TRANSMITTING
TERMINAL DISCLAIMER

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


Accompanying this communication is a Terminal Disclaimer obviating the double patenting rejection over U.S. Patent No. 6,531,506. In view of the terminal disclaimer, Applicants respectfully submit that the claims are now in condition for allowance. The issuance of a Notice of Allowance at an early date is respectfully requested.

in re Kroetz et al.
Application No.10/694,641,
Transmittal of Terminal Disclaimer

PATENT
Attorney Docket No.: 023070-115611US
Client Ref. No.:2000-094-3

If the Examiner believes a telephone conference would expedite prosecution of this application, he is invited to telephone the undersigned at 415-576-0200.

Respectfully submitted,


Laurence J. Hyman
Reg. No. 35,551


TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
Attachment
LJH:ljh
61025256 v1

RECEIVED
CENTRAL FAX CENTER

004/006

APR 09 2007

PTO/SB/26 (09-06)

TERMINAL DISCLAIMER TO OBTAIN A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT	Docket Number (Optional) 023070-115611US
<p>In re Application of: Kroetz et al.</p> <p>Application No.: 10/894,641</p> <p>Filed: 10/27/2003</p> <p>For: Inhibitors of Epoxide Hydrolase for the Treatment of Hypertension</p> <p>The owners, <u>the Regents of the University of California and the Government of the United States, as represented by the Secretary of the Department of Health and Human Services</u>, together of <u>100</u> percent interest in the instant application hereby disclaim, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term prior patent No. <u>6,531,506</u> as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owners hereby agree that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantees, their successor or assigns.</p> <p>In making the above disclaimer, the owners do not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later:</p> <ul style="list-style-type: none"> expires for failure to pay a maintenance fee; is held unenforceable; is found invalid by a court of competent jurisdiction; is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexamination certificate; is reissued; or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer. <p>Check either box 1 or 2 below, if appropriate.</p> <p>1. <input type="checkbox"/> For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.</p> <p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.</p> <p>2. <input checked="" type="checkbox"/> The undersigned is an attorney or agent of record. <u>Reg. No. 35,551</u></p> <div style="display: flex; justify-content: space-between; margin-top: 20px;"> <div style="text-align: center;">  _____ Signature </div> <div style="text-align: center;"> April 9, 2007 _____ Date </div> </div> <div style="display: flex; justify-content: space-between; margin-top: 10px;"> <div style="text-align: center;"> Laurence J. Hyman _____ Typed or printed name </div> <div style="text-align: center;"> 415-576-0200, x 4244 _____ Telephone Number </div> </div> <p><input checked="" type="checkbox"/> Terminal disclaimer fee under 37 CFR 1.20(d) is included.</p> <p style="text-align: center;">WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p> <p><small>*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/98 may be used for making this certification. See MPEP § 324.</small></p>	

61018445 v1

 04/10/2007 TL0111 00000030 201430 10694641
 01 FC:1814 130.00 DA

APR 09 2007

PTO/SB/17 (07-06)

Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL
For FY 2006☐ Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT (\$)** 130**Complete If Known**

Application Number	10/694,841
Filing Date	October 27, 2003
First Named Inventor	Kroetz, Deanna L.
Examiner Name	Brian Yong Kwon
Art Unit	1614
Attorney Docket No.	023070-115611US

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____

☒ Deposit Account Deposit Account Number: 20-1430 Deposit Account Name: Townsend and Townsend and Crew LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17☒ Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2035.

FEE CALCULATION**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Small Entity	Fee (\$)	Small Entity	Fee (\$)	Small Entity	Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES**Fee Description**

Each claim over 20 (including Reissues)

Fee (\$)

Small Entity Fee (\$)

Each independent claim over 3 (including Reissues)

50

25

Multiple dependent claims

200

100

360

180

Total Claims**Extra Claims**

Fee (\$)

Fee Paid (\$)

Multiple Dependent Claims

Fee (\$)

Fee Paid (\$)

-20 or HP =

x

=

HP = highest number of total claims paid for, if greater than 20

Indep. Claims**Extra Claims**

Fee (\$)

Fee Paid (\$)

-3 or HP =

x

=

HP = highest number of independent claims paid for, if greater than 3

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets**Extra Sheets**

Number of each additional 50 or fraction thereof

Fee (\$)

Fee Paid (\$)

- 100 =

/ 50 =

(round up to a whole number) x

=

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)


Fees Paid (\$)

Other (e.g., late filing surcharge): Terminal disclaimer fee under 37 CFR 1.20(d)

130

SUBMITTED BY

Signature

Registration No. 35,551
(Attorney/Agent)

Telephone 415-576-0200

Name (Print/Type)

Laurence V. Hyman

Date 4/9/07

61025801 v1